Arvinas, Inc. (ARVN)

Market Cap	1.22B
Revenue (ttm)	263.40M
Net Income (ttm)	-198.90M
Shares Out	68.77M
EPS (ttm)	-2.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,871,318
Open	18.90
Previous Close	18.37
Day's Range	17.37 - 19.05
52-Week Range	16.61 - 51.51
Beta	1.88
Analysts	Strong Buy
Price Target	58.82 (+231.01%)
Earnings Date	Feb 11, 2025

About ARVN

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 27, 2018
• Employees: 430
• Stock Exchange: NASDAQ
• Ticker Symbol: ARVN
• Website: https://www.arvinas.com

Financial Performance

In 2024, Arvinas's revenue was $263.40 million, an increase of 235.54% compared to the previous year's $78.50 million. Losses were -$198.90 million, -45.85% less than in 2023.

Analyst Forecast

According to 12 analysts, the average rating for ARVN stock is "Strong Buy." The 12-month stock price forecast is $58.82, which is an increase of 231.01% from the latest price.

Price Target

$58.82

(231.01% upside)

Analyst Consensus: Strong Buy